Pegfilgrastim biosimilar - Intas Pharmaceuticals

Drug Profile

Pegfilgrastim biosimilar - Intas Pharmaceuticals

Alternative Names: INTP 5; Lapelga; Neupeg; Pegasta; Pegylated Apo-Filgrastim; Recombinant pegylated granulocyte colony stimulating factor - Intas Biopharmaceuticals

Latest Information Update: 16 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intas Biopharmaceuticals
  • Developer Apotex; Intas Biopharmaceuticals
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 16 Mar 2017 No recent reports of development identified - Phase-III for Neutropenia in Czech Republic, Slovakia, Bulgaria, Greece, and Hungary (SC)
  • 15 Mar 2017 Pegfilgrastim biosimilar is still under Preregistration for Neutropenia in USA (SC)
  • 29 Aug 2016 Intas Pharmaceuticals plans phase I study in healthy volunteers in India (CTRI/2016/07/007096)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top